Quick Answer
Prelude Therapeutics Inc reported Cash and Equivalents of $35.26 million for fiscal year 2025.
Prelude Therapeutics Inc Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $35.26M | +182.6% |
| 2024 | $12.47M | -50.7% |
| 2023 | $25.29M | -17.4% |
| 2022 | $30.61M | -3.8% |
| 2021 | $31.83M | -85.4% |
| 2020 | $218.31M | +1056.4% |
| 2019 | $18.88M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $47.53M | +326.9% | +84.6% |
| June 30, 2025 | $25.75M | -7.5% | -36.1% |
| March 31, 2025 | $40.27M | +63.0% | +222.8% |
| December 31, 2024 | $12.47M | -50.7% | +12.0% |
| September 30, 2024 | $11.13M | -30.0% | -60.0% |
| June 30, 2024 | $27.83M | +5.2% | +12.6% |
| March 31, 2024 | $24.71M | +35.7% | -2.3% |
| December 31, 2023 | $25.29M | -17.4% | +59.1% |
- Prelude Therapeutics Inc showed an increase of +182.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Prelude Therapeutics Inc’s cash and equivalents has grown by 86.7% (from $18.88 million to $35.26 million).
- The most recent figure is from Prelude Therapeutics Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: